The recent resumption of negotiations between AstraZeneca and NHS England concerning the availability of the breast cancer drug Enhertu marks a potentially significant turning point for patients suffering from incurable
Pharmaceutical
197Articles
Poolbeg Pharma PLC, the clinical-stage biopharmaceutical company listed on AIM, has secured a European patent for its POLB 001 treatment targeting cytokine release syndrome induced by cancer immunotherapy. The European
In a landmark development for the realm of pharmacological treatments for obesity, the United Kingdom has recently witnessed the approval of the Wegovy pill, a breakthrough that could redefine the
In a significant development that could alter the landscape of British retail, the private equity owners of Boots, the renowned pharmacy chain, are reportedly in discussions for a sale valued
Ondine Biomedical enters 2026 at a decisive stage in its development. The company is positioning Steriwave, its light activated antimicrobial technology, as a non antibiotic approach to reducing hospital acquired
Citi has identified an attractive risk-reward scenario for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) in advance of headline data from a critical trial of its cardiac treatment Wainua, with results anticipated during
The recent remarks made by Lord Vallance of Balham at The Times Life Sciences Summit have stirred considerable discussion within the United Kingdom’s commercial and scientific communities. As the former
The venerable British pharmacy chain Boots is embarking on a new chapter as it prepares for a potential initial public offering (IPO) that could value the company at £7 billion.
hVIVO PLC, the AIM-listed specialist in human challenge trials, has secured a contract with a new European biotechnology client for an influenza challenge study, marking the third such agreement announced
AstraZeneca has committed to reactivating a £200 million investment at its Cambridge headquarters, alongside a new £100 million funding initiative for its site in Macclesfield. This decision comes in the
In a significant move for the burgeoning psychedelic industry, President Trump signed an executive order aimed at expediting the review of psychedelic therapies, as well as increasing federal research funding.
HM Revenue and Customs has announced a pause in enforcing VAT charges on medicines supplied under early access schemes, amid rising concerns from the pharmaceutical industry. The decision comes after
NHS patients in the United Kingdom are being warned of imminent prescription shortages if a diplomatic resolution is not reached between the United States and Iran. Drug manufacturers have raised
GSK has announced promising results from early trials of a new gynaecological cancer drug, which it aims to fast-track for market release in the coming years. The pharmaceutical giant is
ImmunityBio has announced the implementation of comprehensive regulatory compliance measures following a warning letter from the Food and Drug Administration regarding promotional claims for Anktiva, its bladder cancer treatment. The
A subculture once confined to the margins of competitive bodybuilding has migrated into the mainstream wellness economy at remarkable speed. The proliferation of unregulated peptide compounds, sold openly online and
